# OnCo record paper-checkmate-238-nejm-2017 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-checkmate-238-nejm-2017/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-checkmate-238-nejm-2017" ;
  schema:name "CheckMate 238: adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma"@en ;
  schema:description "A year of adjuvant nivolumab after surgery for high-risk melanoma reduced recurrences more than the previous standard, high-dose ipilimumab, with a quarter of the severe toxicity, making PD-1 blockade the adjuvant standard."@en ;
  schema:url <https://onco.cc/key-papers/paper-checkmate-238-nejm-2017/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:citation <https://doi.org/10.1056/NEJMoa1709030>, <https://pubmed.ncbi.nlm.nih.gov/28891423/> ;
  schema:sameAs <https://doi.org/10.1056/NEJMoa1709030> ;
  schema:datePublished "2017"^^xsd:gYear ;
  schema:author "Weber J, Mandala M, Del Vecchio M, et al." ;
  onco:cancers <https://onco.cc/cancers/stage-iii-melanoma/> ;
  onco:drugs <https://onco.cc/drugs/ipilimumab/>, <https://onco.cc/drugs/nivolumab/> ;
  onco:trials <https://onco.cc/trials/checkmate-238/> ;
  onco:journals <https://onco.cc/journals/nejm/> .